Navana Pharmaceuticals financial analysis: 28% sales growth, BDT 750m interest bill and falling debt (Oct 2026)

Investment considerations: 28% sales growth and falling debt, against 1.97x interest cover and a board held in place by BSEC

Navana Pharmaceuticals PLC makes and sells generic medicines for people and animals in Bangladesh, and exports a small part of its output [1 p.39]. Its fiscal year runs from 1 July to 30 June [1 p.42]; FY2025 is the year to 30-Jun-2025. The company was incorporated in 1986, merged with Navana Healthcare Limited in 2017, changed ownership in 2020 and listed on the Dhaka and Chittagong exchanges on 11 and 12 October 2022 after raising BDT 750m in an IPO [1 p.39] [1 p.235]. It reports standalone accounts; there are no subsidiaries.

The story since the IPO is fast growth paid for with bank debt. Net sales rose from BDT 3,606m in FY2021 to BDT 8,843m in FY2025, an increase of 145% in four years [1 p.240]. The gross margin held between 44% and 46% throughout [16], and selling, marketing and distribution costs fell from 31.9% of sales to 24.9%, so the operating margin rose from 10.1% to 16.7% [16]. But short-term bank loans grew from BDT 1,137m to BDT 5,008m between June 2021 and June 2024 [5 p.8] [1 p.282], and finance expenses rose from BDT 75m to BDT 750m [1 p.240]. In FY2025 interest took half of operating profit, and profit after tax rose only 20.6% while sales rose 28.2% [1 p.283].

The turn came in FY2025. Operating cash flow jumped to BDT 1,815m from BDT 707m, the company stopped borrowing for capex, and short-term loans fell by BDT 725m [1 p.285]. By 31-Mar-2026 total borrowings were BDT 3,776m, down 28% from the June 2024 peak [16]. Nine-month FY2026 finance expenses fell 20.4% while sales grew 26.1% [2 p.3], and the board reported FY2026 EPS of BDT 5.93 against BDT 4.54 [12].

Business: a human and animal generics maker with 18% of sales from veterinary products and 4% from exports

How the company makes money. Navana sells generic finished medicines in tablet, capsule, liquid, powder, sachet, cream, injection and eye or nasal drop forms for human use, and bolus, liquid, injection and water-soluble powder forms for animals [1 p.39]. Local human and animal sales are booked when goods leave the depots; institutional and export sales when they leave the factory [1 p.279]. Revenue is reported gross and net of VAT: FY2025 gross sales were BDT 10,113m and VAT BDT 1,270m [1 p.306].

Three revenue lines. Of FY2025 net sales, local human health was BDT 6,897m, local animal health BDT 1,568m and exports BDT 378m [1 p.306]. On the company's gross-sales basis the mix was 80.4% human, 16.2% veterinary and 3.7% export, against 76.9%, 17.2% and 5.8% in FY2021 [1 p.233]. Human health is therefore taking share inside the company, veterinary is roughly stable and exports have shrunk as a share, though they grew 49.6% in FY2025 [16].

Animal health is the distinctive part. Veterinary, poultry and fisheries products are managed as a separate reportable segment [1 p.315]. Net animal-health sales rose 16.6% in FY2025, slower than human health (+30.1%) [16]. The segment note allocates finance cost, operating expense and tax across the two segments: both earned a pre-tax margin of 6.5% on gross revenue in FY2025, which means the allocation follows revenue and says little about the true profitability of each line [1 p.315] [16].

Exports. International sales started in 2001 [1 p.39]. Export sales were BDT 378m in FY2025 (BDT 253m in FY2024) and export receivables BDT 87m [1 p.306] [1 p.299]. The company earned BDT 20.4m of export cash incentive, 5.4% of export sales [1 p.311]. The annual report does not name export markets in the pages we read. In January 2026 the board approved a subsidiary or liaison office in Sri Lanka [12].

Market position. The directors describe Navana as one of the fastest-growing companies in the sector and say it holds a good position in the IMS MAT ranking [1 p.22] [1 p.39], but the pages we read give no rank or market share. That is a gap: an investor cannot yet test whether 28% growth came from gaining share or from price increases.

History: sales up 3.8 times since FY2017, profit up 6.6 times, but ROE never above 10.4%

Eight years of history. We have audited statements for FY2017, FY2018 and FY2020-FY2025; the FY2019 accounts are not in our corpus [7 p.4] [6 p.9] [1 p.240]. Net sales grew from BDT 2,343m (FY2017) to BDT 8,843m (FY2025). Growth was 10.2% in FY2018, then 14.5% in FY2021, 31.9% in FY2022, 19.9% in FY2023, 20.9% in FY2024 and 28.2% in FY2025 [16]. The acceleration began after the 2020 ownership change [1 p.39].

Profit did not keep up with sales because of interest. Operating profit rose from BDT 364m (FY2021) to BDT 1,480m (FY2025), four times, but profit after tax only 2.4 times, from BDT 202m to BDT 488m [16]. The difference is finance expenses, which went from 2.1% of sales to 8.5% [16]. ROE has stayed between 3.1% and 10.4% in every year we can measure [16].

Equity jumped twice for non-operating reasons. In FY2018 land was revalued, adding BDT 1,467m of other comprehensive income [7 p.4]; in FY2023 the IPO added BDT 272m of share capital and BDT 448m of share premium [4 p.248]. A capital reserve of BDT 606m appeared in FY2022 [5 p.8]. These inflate the equity base, which is one reason ROE looks low; revaluation reserve was still BDT 1,671m at June 2025 [1 p.282].

Line items: volume drove sales; materials, the taka and a 13.7% loan rate drove costs

Revenue. The company attributes FY2025 sales growth to 'strong branding, marketing and improved economic condition' [1 p.306] and, in the directors' report, to 'huge volume of sales' [1 p.239]. Volume did rise: actual production went from 634m to 835m units (+31.7%) [1 p.317], close to the 28.2% sales growth, so most of FY2025 growth looks volume-led. Medicine prices are set with the Directorate General of Drug Administration (DGDA): the auditor tested inventory values against 'selling price approved by Directorate General of Drug Administration' [1 p.279]. The filings do not say what share of sales is under DGDA price control.

Cost of goods sold and the taka. Raw materials consumed rose 39.4% to BDT 3,308m and packing materials 38.6% to BDT 1,343m in FY2025, faster than sales; together they were 52.6% of net sales against 48.4% a year earlier [1 p.307] [16]. That is why the gross margin slipped from 45.6% to 44.2% [16]. The company lists currency risk on raw-material imports as a high-impact risk [1 p.203] but does not disclose the value or share of imported materials in the pages we read. Two lines show the exposure: a foreign-exchange loss of BDT 54.1m (BDT 25.2m in FY2024) in other income [1 p.311], and advance tax deducted at the import stage of BDT 118.3m against BDT 99.4m [1 p.300]. LTR and UPAS (usance payable at sight) loans, which finance imports, were BDT 1,317m at June 2025 [1 p.305].

Factory expenses rose 29.9% to BDT 665m, mostly depreciation (BDT 209m from BDT 120m) as BMRE machinery and the cephalosporin and utility buildings came into use, and electricity (BDT 49.7m from BDT 28.4m) [1 p.307] [1 p.308]. Property, plant and equipment additions were BDT 915m in FY2025 [1 p.297].

Selling cost. Selling and marketing expenses were BDT 1,642m and distribution expenses BDT 562m in FY2025, together 24.9% of net sales [1 p.283]. The largest items are people: salary and allowances BDT 844m, daily expenses for field workers BDT 278m, festival bonus BDT 78m and distribution salaries BDT 190m, together 63.1% of the total [1 p.309] [1 p.310] [16]. The company had 4,798 employees at June 2025, up from 4,408 [1 p.316]. Selling cost grew 15.2% while sales grew 28.2% [16], which is the main reason the operating margin improved. In 9M FY2026 the trend reversed: selling, marketing and distribution rose to 28.5% of sales from 27.0% [2 p.3] [16].

Finance expenses. Interest on short-term loans was BDT 637m in FY2025 against BDT 439m [1 p.311]. On average short-term loans that is an implied rate of 13.7%, up from 9.7% [16]. Every 1 percentage point on the June 2025 short-term loan balance of BDT 4,283m is about BDT 43m of annual interest, 8.8% of FY2025 profit after tax [16]. Finance expenses also include BDT 16.0m of BO charges and interest on a margin loan used to invest in listed shares [1 p.311].

Other income and tax. Other income was a loss of BDT 33.9m in FY2025, because of the BDT 54.1m FX loss and a BDT 10.5m realised loss on listed shares [1 p.311]. The company still holds shares bought for BDT 182.7m with a market value of BDT 34.5m at June 2025, an unrealised loss of BDT 148.3m [1 p.298]. Income tax was BDT 174m, an effective rate of 26.3% [16].

Capacity and IPO money: plants at 98% and IPO funds 97% spent, with a EUR 26.6m loan next

Capacity. Total installed capacity was 851.6m units in FY2025 against 769.6m, and production was 834.5m units, so utilisation rose from 82% to 98% [1 p.317]. Tablets, capsules, syrup and bolus ran at 99% and ointments at 99%; injections were at 56% and powders at 58% [1 p.317]. High utilisation in the main oral line means more volume growth needs new capacity.

IPO proceeds. The 2022 IPO raised BDT 750m [1 p.235]. By 30-Jun-2025 the company had used BDT 727.7m (97%), on a new generic production unit (BDT 131.1m of 131.2m budgeted), refurbishment of the cephalosporin unit (BDT 178.5m), a new utility and engineering building (BDT 97.3m), the general liquid facility (BDT 46.8m), part repayment of loans (BDT 211.8m) and IPO costs (BDT 30.0m) [1 p.235]. The animal-health facility upgrade had used only BDT 32.0m of BDT 54.4m, leaving BDT 22.4m (41%) unspent; the BDT 15.0m spent in July-December 2024 was LC margin [1 p.235]. All projects were due within 36 months of receiving the money [1 p.235], which on the October 2022 listing dates means about October 2025.

Capex beyond the IPO. Capital work-in-progress was BDT 821m at June 2025; additions of BDT 301m in FY2025 and BDT 939m in FY2024 were labelled 'BMRE and machinery' [1 p.297]. Advances for capital expenditure were a further BDT 605m (BDT 921m in June 2024) [1 p.299]. Three new projects followed: a herbal division of about 10,000 sq ft costing about BDT 208.5m and expected to add about BDT 400m of revenue in its first year, to be completed within five years (board decision 15-Jan-2025); a generic production project approved on 28-Jan-2026; and a decision on 3-Jun-2026 to proceed with a EUR 26.61m, 12-year foreign loan from AKA Ausfuhrkredit-Gesellschaft of Frankfurt to expand production, subject to regulatory approval [12]. The filings do not yet give the project cost or the taka amount.

Balance sheet: 95% of debt is short-term, and a BDT 1.39bn VAT demand sits off the books

Debt. Borrowings excluding leases were BDT 880m in June 2020 and BDT 5,269m in June 2024, then fell to BDT 4,488m in June 2025 and BDT 3,776m in March 2026 [16]. Almost all of it is short-term: at June 2025, bank overdraft BDT 1,854m, LTR and UPAS loans BDT 1,317m, time loans BDT 990m and a margin loan BDT 122m [1 p.305]. Long-term loans were only BDT 142m. All inventory is pledged as security for the loans [1 p.298]. Net debt/equity peaked at 1.10x and was 0.67x at March 2026 [16].

Where the borrowed money went. Between June 2021 and June 2023 advances, deposits and prepayments grew from BDT 444m to BDT 2,126m, 22% of total assets [5 p.8] [4 p.248]. At June 2025 they were BDT 1,669m, of which advance income tax was BDT 669m and advance for capital expense BDT 605m [1 p.299]. The rest of the debt funded plant, inventory and receivables. The note states no advances were due from directors or companies under the same management [1 p.300].

Working capital. Inventory days fell from 160 (FY2020) to 115 (FY2025) and payable days rose from 77 to 120, which released cash [16]. Receivable days rose to 57 from 51 two years earlier [16]; receivables aged three to six months jumped to BDT 278m from BDT 66m, though those over a year fell to BDT 11m [1 p.299]. Payables include BDT 205m of interest payable on short-term loans and BDT 258m of tax and VAT deducted at source on capex not yet paid over [1 p.305].

Contingent liabilities. Contingent liabilities were BDT 1,525m at June 2025 [1 p.314]. The largest is a BDT 139.45 crore demand from the Large Taxpayers Unit (VAT Audit) dated 12-May-2024, alleging irregular input tax credit and non-deduction of VAT at source; the company rebutted it, appealed to the NBR chairman on 15-Sep-2024, and expected a hearing on 11-Nov-2025 [1 p.314]. No provision has been made. Smaller VAT and tax cases total about BDT 130m, including BDT 8.7m relating to past audits of Navana Health Care [1 p.314]. The auditor, A. Qasem & Co., gave an unmodified opinion with an emphasis of matter on the VAT demand [1 p.278].

Cash quality. Operating cash flow was weak before FY2024: BDT 122m, 199m and 94m in FY2021-FY2023, below profit each year [1 p.240]. It rose to BDT 707m in FY2024 and BDT 1,815m in FY2025 [1 p.285]. Two cautions: the company reports interest paid in financing activities, so CFO after interest paid was BDT 1,116m in FY2025 [16]; and part of the FY2025 jump came from a BDT 482m fall in advances and a BDT 417m rise in payables [1 p.318], which may not repeat.

Latest results: FY2026 EPS up 31% to BDT 5.93, driven by lower interest rather than margins

Nine months to March 2026. Net sales were BDT 8,329m, up 26.1%, and profit after tax BDT 493m, up 31.6% [2 p.3] [16]. The mix of the gain changed. Gross margin fell to 44.8% from 46.0%, selling, marketing and distribution rose to 28.5% of sales and administrative expenses rose 34%, so operating profit grew only 4.9% and the operating margin fell to 13.8% from 16.6% [16]. Profit grew because finance expenses fell 20.4% to BDT 451m [2 p.3]. In the March quarter alone sales rose 22.1% and profit 20.8%, with a tax charge of only BDT 4.4m after a deferred-tax credit [2 p.3].

FY2026 as announced. The board met on 28-Oct-2026 and reported FY2026 EPS of BDT 5.93, NAV per share of BDT 51.06 and operating cash flow per share of BDT 18.59, against BDT 4.54, 45.29 and 16.90 [12]. On 107.42m shares, EPS of 5.93 implies profit after tax of about BDT 637m, up about 31%; the fourth quarter implied EPS of BDT 1.34 [12] [2 p.3]. The audited FY2026 statements were not in our corpus at the time of writing; this note will be updated when they are.

Ratios and peers: fastest growth of five, but interest cover of 2.0x against 10.8x at IBN SINA

Returns. ROE (on average equity) rose from 6.3% in FY2021 to 10.4% in FY2025 [16]. The DuPont parts: net margin 5.5%, asset turnover of about 0.77x and assets/equity of 2.36x [16]. The margin is thin because of interest, and the equity base carries BDT 1,671m of land revaluation [1 p.282].

Peers, same basis. Exhibit 22 compares FY2025 (year to 30-Jun-2025) figures from each company's own annual report, using each company's own label for selling cost and finance cost. Navana grew fastest of the five (+28.2%) with Asiatic close behind (+27.4%) [16]. Its gross margin of 44.2% is above IBN SINA (40.4%) and ACME (42.3%) and below Beacon (52.0%) [8 p.204] [9 p.167] [10 p.190]. Its 'selling & marketing' plus 'distribution' expenses at 24.9% of sales are lower than IBN SINA's 'selling & distribution expenses' (30.2%) and Beacon's 'marketing, selling & distribution expenses' (26.9%), but 5.9pp above ACME's 'selling, marketing and distribution expenses' (19.0%) [16]. Asiatic reports a single 'operating expenses' line, so its selling cost cannot be separated [11 p.70].

On leverage, Navana's 'finance expenses' were 8.5% of sales, similar to ACME's 'financial expenses' (9.1%) and below Beacon's 'finance expenses' (10.4%) and Asiatic's 'financial expenses' (10.9%), but far above IBN SINA's 'financial charges' (0.7%) [16]. Interest cover was 2.0x at Navana against 10.8x at IBN SINA, 2.1x at ACME, 1.8x at Beacon and 2.8x at Asiatic [16]. Borrowings/equity was 0.92x, in line with ACME (0.93x), below Beacon (1.51x) and above IBN SINA (0.52x) and Asiatic (0.21x) [16].

Multiples as facts. At BDT 59.3 on 29-Oct-2026 the shares trade at 10.0x FY2026 EPS and 1.16x the June 2026 NAV per share [15] [12]. At the 30-Jun-2025 DSE price of BDT 50.30 [1 p.147], the figures were 11.1x FY2025 EPS and 1.11x NAV [16]. The FY2026 cash dividend of BDT 0.60 is a 1.0% yield [12].

Governance: a 2020 ownership change, a BSEC direction of 18-Jun-2026 on board composition, and cash dividends for general shareholders only

Ownership and the Navana name. The company was founded in 1986 and amalgamated with Navana Healthcare Limited in 2017; in 2020 'ownership of the company changed to the current structures, and simultaneously the Board and management were reformed' [1 p.39]. The current shareholders on the board are individuals and one company: managing director Professor Dr. Md. Jonaid Shafiq 6.74%, director Mrs. Masuma Parvin 7.35%, Stratus Holdings Limited 8.11% (nominee Mr. Khondaker Sabbir Mohammad Kabir), Dr. Sayeed Ahmed 2.46%, Mr. Javed Kaiser Ally 2.33%, Mrs. Tarana Ahmed 2.33% and sponsor Mr. Manzurul Islam 2.33% [1 p.106]. Sponsors and directors held 31.64%, foreign investors 19.63%, institutions 9.42% and the general public 39.31% at June 2025 [1 p.105]. The filings we read do not describe any shareholding or trading link with other companies that carry the Navana name.

Related parties. The related-party note lists only directors: remuneration of BDT 4.3m (managing director) and BDT 3.8m (deputy managing director), and interest-free loans from five directors totalling BDT 30.0m, unchanged during FY2025 [1 p.313]. No sales to, purchases from, or receivables from group companies are disclosed, and receivables and advances due from directors or companies under common management are stated as nil [1 p.299] [1 p.300]. The board held 16 meetings in FY2025 [1 p.313].

Board events in 2026, from DSE notices. Mrs. Saiqa Mazed had been appointed chairman with effect from 24-Jun-2025 [12]. On 28-Jan-2026 the board elected Mr. Javed Kaiser Ally chairman and appointed Dr. Sayeed Ahmed managing director; on 29-Jan-2026 it appointed Mr. Md. Aminul Hoque Bhuiyan, ACS as acting company secretary [12]. On 1-Jun-2026 the company said Mr. Lorens Shamol Mollick 'continues to legally hold his position' as company secretary [12]. On 27-Aug-2026 it disclosed that, under a BSEC direction dated 18-Jun-2026, its 64th board meeting was postponed and the board was to stay as it stood at the 63rd meeting, with Mrs. Saiqa Mazed as chairman and independent director and Professor Dr. Md. Jonaid Shafiq as managing director [12]. Sponsor Mr. Manzurul Islam then transferred 1,604,603 shares to Dr. Jonaid Shafiq outside the trading system, completed by 1-Oct-2026 [12]. The FY2025 statements were signed by an 'Acting Managing Director' [1 p.282]. The Q3 FY2026 board meeting was held on 3-Jun-2026, against 29-Apr-2025 for the same quarter a year earlier [12].

Dividend record. The company declared 11% cash for FY2022 and 13% cash for FY2023, the latter approved for all members on the 19-Nov-2023 record date [1 p.23] [3 p.101]. For FY2024 and FY2025 it paid 14% cash to general shareholders only; for FY2025 the sponsors and directors, holding 33,989,714 shares, received nothing and the payout was BDT 47.5m, 9.7% of profit [1 p.231] [12] [16]. For FY2026 the board recommended 6% cash and 8% stock, the stock 'to utilize them for business expansion', with record date 24-Nov-2026 and AGM 20-Dec-2026 [12]. Cash paid to shareholders is small next to the BDT 699m of interest paid in FY2025 [1 p.285].

Other capital actions. A partially convertible bond was under-subscribed: BDT 80m was raised in FY2024 [1 p.285], and on 1-Sep-2025 the board decided to repay it early without conversion, subject to BSEC approval [12]. National Credit Ratings rated the company AA long term and ST-2 short term (stable) in December 2024 and December 2025 [12].

What's next: an 8% stock dividend on 24-Nov-2026, a EUR 26.6m loan and LDC graduation now in 2029

What will move the line items next, with dates. LDC graduation is now set for 24-Nov-2029: the UN General Assembly adopted the three-year deferral from 24-Nov-2026 on 29-Oct-2026 in New York (30-Oct in Dhaka) [13] [14]. Navana's export cash incentive was BDT 20.4m in FY2025 [1 p.311], so the direct effect on other income is small.

The other dated items are company events. The 8% stock dividend would raise the share count from 107.42m to about 116.01m after the 24-Nov-2026 record date if approved at the 20-Dec-2026 AGM, diluting per-share figures by 7.4% [12]. The EUR 26.61m loan, if approved by regulators, adds long-term foreign-currency debt and interest, and moves the FX exposure from imports onto the balance sheet [12]. The herbal division (BDT 208.5m) is due within five years of the 15-Jan-2025 board decision [12].

Risks: interest and refinancing first, then the taka, a BDT 1.39bn VAT demand and the BSEC-directed board

Each risk is tied to the line it moves; FY2025 profit before tax of BDT 662m is the yardstick [1 p.283].

Interest rates are the largest sensitivity. In FY2025 every 1pp on the June 2025 short-term loans equalled about BDT 43m of interest, 6.5% of profit before tax [16]. The taka is second: materials were 52.6% of sales [16], and the FX loss doubled to BDT 54m [1 p.311]. The VAT demand of BDT 1,394.5m would exceed two years of FY2025 profit before tax if it were upheld in full [1 p.314]. The 2026 board changes and the BSEC direction add a governance risk that the filings do not quantify [12].

Key questions: debt after the euro loan, the source of growth, and the VAT case

FAQ

When does Navana Pharmaceuticals' fiscal year end?

30 June. FY2025 is the year from 1-Jul-2024 to 30-Jun-2025 [1 p.42] [1 p.283].

What dividend did Navana declare for FY2026?

6% cash and 8% stock (14% in total), record date 24-Nov-2026, AGM 20-Dec-2026 [12].

How much debt does Navana have?

BDT 3,776m excluding leases at 31-Mar-2026, mostly short-term bank loans, down from BDT 5,269m at June 2024 [16].

Does Navana make veterinary products?

Yes. Local animal-health sales were BDT 1,568m net of VAT in FY2025, 17.7% of net sales [1 p.306].

How were the IPO proceeds used?

Of BDT 750m, BDT 727.7m was used by June 2025 on new and refurbished production units, a utility building, loan repayment and IPO costs; BDT 22.4m for the animal-health facility was unspent [1 p.235].

Which results does this note use?

Audited annual statements for FY2017, FY2018 and FY2020-FY2025, and the unaudited nine months to 31-Mar-2026. The FY2026 annual report was not yet in our corpus; only the DSE-announced FY2026 EPS, NAV and dividend are used.

Sources

1. Navana Pharmaceuticals PLC Annual Report 2024-25 (year to 30-Jun-2025) · link · accessed 2026-10-31
2. Navana Pharmaceuticals PLC un-audited interim financial statements, 1-Jul-2025 to 31-Mar-2026 · link · accessed 2026-10-31
3. Navana Pharmaceuticals Limited Annual Report 2023-24 (AGM minutes for FY2023) · link · accessed 2026-10-31
4. Navana Pharmaceuticals Limited Annual Report 2022-23 (statement of financial position) · link · accessed 2026-10-31
5. Navana Pharmaceuticals Limited audited financial statements, year to 30-Jun-2022 · link · accessed 2026-10-31
6. Navana Pharmaceuticals Limited audited financial statements, year to 30-Jun-2021 · link · accessed 2026-10-31
7. Navana Pharmaceuticals Limited audited financial statements, year to 30-Jun-2018 · link · accessed 2026-10-31
8. The IBN SINA Pharmaceutical Industry PLC Annual Report 2024-25 (consolidated statements) · link · accessed 2026-10-31
9. The ACME Laboratories Ltd. Annual Report 2024-25 · link · accessed 2026-10-31
10. Beacon Pharmaceuticals PLC Annual Report 2024-25 · link · accessed 2026-10-31
11. Asiatic Laboratories Limited Annual Report 2024-25 · link · accessed 2026-10-31
12. Dhaka Stock Exchange news archive for NAVANAPHAR, Nov-2024 to Oct-2026 (results, dividend declarations, board and BSEC notices, loan and project decisions) · link · accessed 2026-10-31
13. The Daily Star, 'Bangladesh gets 3 more years for LDC graduation' (30-Oct-2026, UN decision of 29-Oct-2026) · link · accessed 2026-10-31
14. The Business Standard, 'Bangladesh gets 3 more years before LDC graduation' (30-Oct-2026) · link · accessed 2026-10-31
15. AnalystBro price data (TradingView feed): DSE:NAVANAPHAR daily and monthly bars to 29-Oct-2026 · link · accessed 2026-10-31
16. AnalystBro model for this report (workbook tabs below) · link · accessed 2026-10-31